annb0t
Top 20
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the presentation of new data from an ongoing phase 1 trial of paxalisib in combination with radiotherapy for brain metastases. Interim data from the first stage of the study reports that all nine evaluable patients experienced a complete or partial response, representing an overall response rate (ORR) of 100%. A typical ORR associated with whole brain radiotherapy alone can commonly range from 20-45% in published studies. Also Read:Kazia Shares...
>>> Read more: Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
>>> Read more: Kazia Therapeutics Shares Jump On Interim Data From Paxalisib Combo Study In Brain Metastases
